Inventor · disambiguated record
Sebastian Bunk
Also filed as: BUNK SEBASTIAN
40 granted patents·29 pending applications·270 citations·filing 2013–2025
97Inventor score
Files withIMMATICS BIOTECHNOLOGIES GMBH64BAXALTA INC3HEINRICH HEINE UNIVERSITÄT1TAKEDA PHARMACEUTICALS CO1
Top patents by PatentIndex Score
69 records- 0198US11111294B2T cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Sep 7, 2021·11 cites·15 claims
- 0298US10723796B2T cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jul 28, 2020·22 cites·20 claims
- 0398US10590194B2T cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Mar 17, 2020·23 cites·17 claims
- 0497US10889629B2Transfected T-cells and T-cell receptors for use in immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jan 12, 2021·4 cites·20 claims
- 0597US10800832B2T cell receptors and immune therapy using the same against prame positive cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Oct 13, 2020·19 cites·14 claims
- 0697US10800845B2T cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Oct 13, 2020·12 cites·19 claims
- 0797US10725044B2T cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Jul 28, 2020·12 cites·30 claims
- 0897US10702609B2T cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jul 7, 2020·14 cites·33 claims
- 0997US10626160B2Transfected T-cells and T-cell receptors for use in immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Apr 21, 2020·14 cites·20 claims
- 1097US10596242B2Transfected T-cells and T-cell receptors for use in immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Mar 24, 2020·12 cites·20 claims
- 1197US10550182B2T cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2017·Granted Feb 4, 2020·15 cites·8 claims
- 1297US10526407B2T cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Jan 7, 2020·17 cites·24 claims
- 1397US10527623B2T cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2017·Granted Jan 7, 2020·13 cites·9 claims
- 1496US10618956B2Engineered T cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Apr 14, 2020·13 cites·16 claims
- 1595US11104894B2Method for preparing electrocompetent yeast cells, and method for using said cellsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Aug 31, 2021·3 cites·18 claims
- 1695US11072645B2T cell receptors with improved pairingIMMATICS BIOTECHNOLOGIES GMBH·Filed 2017·Granted Jul 27, 2021·10 cites·5 claims
- 1795US10538573B2Transfected T-cells and T-cell receptors for use in immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2017·Granted Jan 21, 2020·20 cites·21 claims
- 1894US10889645B2Engineered T cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jan 12, 2021·3 cites·20 claims
- 1993US10537624B2Transfected T-cells and T-cell receptors for use in immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2017·Granted Jan 21, 2020·15 cites·13 claims
- 2091US10874731B2T cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2017·Granted Dec 29, 2020·4 cites·15 claims
- 2190US11840577B2Antigen binding proteins specifically binding MAGE-AIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Dec 12, 2023·2 cites·9 claims
- 2290US2025154246A1Novel t cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 2389US11236145B2T cell receptors and immune therapy using the same against PRAME positive cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Feb 1, 2022·3 cites·25 claims
- 2489US11111286B2T cell receptors and immune therapy using the same against PRAME positive cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Sep 7, 2021·3 cites·20 claims
- 2589US10683495B2Method for preparing electrocompetent yeast cells, and method for using said cellsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2017·Granted Jun 16, 2020·3 cites·19 claims
- 2686US2025361300A1Improved dual specificity polypeptide moleculeIMMATICS BIOTECHNOLOGIES GMBH·Filed 2025·Application pending·0 cites
- 2784US2024279308A1Transfected t-cells and t-cell receptors for use in immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 2884US2023348598A1Improved dual specificity polypeptide moleculeIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 2984US2024228611A1Novel engineered t cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 3083US12269881B2Antigen binding proteins specifically binding MAGE-AIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Granted Apr 8, 2025·0 cites·8 claims
- 3182US2023321208A1Transfected t-cells and t-cell receptors for use in immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 3281US2024285779A1Novel t cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 3379US2024052054A1Antigen binding proteins specifically binding mage-aIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 3478US2022185888A1Dual specificity polypeptide moleculeIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
- 3578US2022195044A1Dual specificity polypeptide moleculeIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
- 3677US11859009B2Antigen binding proteins specifically binding PRAMEIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Jan 2, 2024·0 cites·30 claims
- 3777US2025051445A1Bma031 antigen binding polypeptidesIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 3877US2024092933A1Antigen binding proteins specifically binding prameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 3977US2025122302A1Antigen binding proteins specifically binding ct45IMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 4076US2021388079A1Novel t cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Application pending·0 cites
- 4175US11945854B2Transfected T-cells and T-cell receptors for use in immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Apr 2, 2024·0 cites·20 claims
- 4275US11932689B2Engineered T cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Mar 19, 2024·0 cites·20 claims
- 4375US10494418B2IgG stimulated remyelination of peripheral nervesBAXALTA INC·Filed 2017·Granted Dec 3, 2019·1 cites·64 claims
- 4475US2025019406A1Sorting with counter selection using sequence similar peptidesIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 4575US2023357428A1Antigen binding proteins specifically binding prameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 4673US12209137B2Antigen binding proteins specifically binding CT45IMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Jan 28, 2025·0 cites·64 claims
- 4773US11730796B2Transfected t-cells and t-cell receptors for use in immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Aug 22, 2023·0 cites·24 claims
- 4873US2020216518A1IgG STIMULATED REMYELINATION OF PERIPHERAL NERVESBAXALTA INC·Filed 2019·Application pending·0 cites
- 4972US12297252B2T cell receptors with improved pairingIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted May 13, 2025·0 cites·10 claims
- 5072US2021300997A1IgG STIMULATED REMYELINATION OF PERIPHERAL NERVESTAKEDA PHARMACEUTICALS CO·Filed 2021·Application pending·0 cites
Showing the top 50 of 69 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Sebastian Bunk files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →